Business
Tilray® Receives the First and Only Market Authorization to Offer Medical Cannabis Products in Portugal
With new market authorization, Tilray confirms its development in the international medical cannabis sector and its leadership position in the EMEA region
About this update from Tilray Brands, Inc.
[{"type":"text","content":"\nWith new market authorization, Tilray confirms its development in the international medical cannabis sector and its leadership position in the EMEA region\n\nPortugal will become the 16th country where patients can access Tilray medical cannabis products\n\n NANAIMO, British Columbia--(BUSINESS WIRE)--\nTilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that it has received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from its GMP-certified EU facility in Cantanhede, Portugal. The market authorization was issued by Infarmed, the Portuguese National Authority of Medicines and Health Products, whose rigorous process in providing such consent is internationally recognized.\n\nThis is the first time a full quality dossier was required and delivered to obtain market authorization in Europe for a medical cannabis product, and that process is now complete. Infarmed’s approval confirms the quality and safety standards of Tilray’s Good Manufacturing Processes (GMP) certified production.\n\nAccording to Infarmed and Portuguese Medicinal Cannabis regulations, Tilray medical cannabis products are approved for the treatment of Spasticity associated with Multiple Sclerosis or spinal cord injuries; nausea, vomiting (resulting from chemotherapy, radiation therapy, and combined HIV medication for hepatitis C); appetite stimulation in the palliative care of patients undergoing oncological treatment or with HIV/AIDS; Tourette syndrome, Epilepsy, and treatment of severe seizure disorders in children; therapeutic-resistant Glaucoma and chronic pain (associated with oncological or nervous system diseases such as neuropathic pain injury caused by nerve damage, phantom limb pain, trigeminal neuralgia, or after herpes zoster).\n\nBrendan Kennedy, Tilray’s Chief Executive Officer, said, \"Tilray is committed to quality and patient safety, and we look forward to significantly improving the quality of lives of Portuguese patients through our medical cannabis products.\"\n\nSascha Mielcarek, Tilray's Managing Director in Europe, says, \"We are very proud of Infarmed's market authorization, which confirms Tilray’s medical cannabis products live up to the highest national and inte...